摘要
Benzbromarone (BM) is a potent URAT1 inhibitor approved for the treatment of gout. However, the low URAT1-selectivity and hepatotoxcity limit its clinical use. To solve these problems, we rationally designed and syn-thesized a series of BM derivatives by chemotype hybridization and bioisosteric replacement. Most compounds exhibited potent inhibitory activities against URAT1 with IC50 values ranging from 5.83 mu M to 0.80 mu M. Among them, JNS4 exhibited the highest URAT1 inhibitory activity with an IC50 of 0.80 mu M, comparable to that of BM (IC50 = 0.53 mu M). Molecular dynamic simulations showed that JNS4 formed 7C-cation interaction with R477, the same as BM. Different from BM, JNS4 bound to W357 and H245 via 7C-7C interactions and formed a hydrogen bond with S35, which might contribute to the high URAT1 binding affinity of JNS4. JNS4 hardly inhibited GLUT9 (IC50 > 20 mu M), another urate reabsorption transporter. In addition, JNS4 showed little inhibitory effects against OAT1 and ABCG2 with IC50 of 4.04 mu M and 10.16 mu M, respectively. Importantly, JNS4 displayed higher in vivo urate-lowering effects at doses of 1-4 mg/kg in a mouse model of hyperuricemia, as compared to BM and lesinurad. Furthermore, JNS4 possessed favorable pharmacokinetic properties with an oral bioavailability of 55.28%, significantly higher than that of BM (36.11%). Moreover, JNS4 demonstrated benign toxicity profiles (no cytotoxicities against HepG2 and HK2 cells; no hepatic and renal toxicities observed in vivo). Collectively, these results suggest that JNS4 represents a novel, safe and selective URAT1 inhibitor with excellent drugg-abilities and is worthy of further investigation as an anti-hyperuricemic agent.
学科与关键词
- Design, Synthesis and Biological Activity of Low-Molecular-Weight URAT1 InhibitorsChen, Siliang; Chen, Ya; Yang, Zhongcheng; Huang, Wanqiu; Cao, Zhijun; Wang, Xuekun; Yao, Huixin; Li, Zheng*; Wang, Guangji*ChemistrySelect, 2023, 8(5).
- Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromaroneHuang, Wanqiu; Jiao, Shixuan; Chen, Siliang; Chen, Ya; Yang, Zhongcheng; Wang, Wenxin; Cao, Zhijun; Li, Zheng; Zhang, Luyong*Bioorganic and Medicinal Chemistry, 2022, 75: 117073.
- Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemiaZhao, Zean; Liu, Jin; Kuang, Peihua; Luo, Jian; Surineni, Goverdhan; Cen, Xiaolin; Wu, Ting; Cao, Ying; Zhou, Pingzheng; Pang, Jianxin*; Zhang, Qun*; Chen, Jianjun*European Journal of Medicinal Chemistry, 2022, 229: 114092.被引 9
